Drug updated on 4/16/2024
| Dosage Form | Tablet (oral: decitabine/cedazuridine 35 mg/100 mg) |
| Drug Class | Nucleoside metabolic inhibitors and cytidine deaminase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Inqovi (decitabine and cedazuridine) Prescribing Information. | 2022 | Taiho Oncology, Inc., Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Decitabine-cedazuridine (Inqovi) for MDS - Final clinical guidance report. | 2021 | CADTH |